Elekta Earns Top Customer Marks from MD Buyline for 2nd Quarter 2010

Customer satisfaction ratings high for linear accelerators, SRS, treatment planning and OIS systems

Atlanta, GA Afghanistan — Tuesday, August 17, 2010

MD Buyline reports that Elekta’s linear accelerators, stereotactic radiosurgery (SRS), oncology information management and treatment planning systems received the highest user satisfaction ratings when compared to other vendors in the industry.

Vendors are rated on a 1 to 10 scale according to user satisfaction with system performance, system reliability, system installation/implementation, applications training, service response time, and service repair quality. MD Buyline clinical and IT analysts conduct interviews with hands-on users, including clinicians, physicians, biomedical engineers, physicists, nurses, CIOs, and IT managers.

Users evaluating linear accelerator providers gave high ratings to Elekta VMAT delivery for its accuracy and speed and continue to appreciate the high functionality the system offers, according to the MD Buyline survey. Strong improvements in system performance and reliability ratings, as well as installation and implementation ratings, helped push Elekta’s treatment systems to the top ranking. Elekta’s total composite score was 9.3 out of 10.

Elekta led two other vendors in user satisfaction ratings for treatment planning systems. Ratings were improved for the third consecutive quarters in assessments of system performance, reliability, installation/implementation and application training, and consistent with last quarter’s ratings for service response time and repair quality. The report indicated that “remote service prevents a lot of unnecessary site visits by engineers and helps dosimetrists/physicists get back to work quickly.” Elekta’s composite score was 8.9.

Elekta SRS systems continued to earn good to excellent ratings among customers, with user satisfaction improvements in system reliability, installation/implementation, service response time and repair quality, and composite rating. Elekta’s composite score was 9.0, up from 1st quarter 2010.

Elekta’s MOSAIQ® oncology information system maintained its steady ratings from the previous quarter and led its other major competitor across the evaluable categories of system performance and reliability, installation/implementation, applications training, and service response time and repair quality. The report indicated that Elekta application “trainers were described as excellent,” and that in the service repair quality area, “users appreciate that the engineers work for the customer, not the clock.” Elekta’s compositing rating was 8.5, up from 1st quarter 2010.

“We are pleased to receive tangible evidence that our efforts to listen to customers about their clinical needs—and then deliver value based on this input—is producing positive results over the last three quarters,” says Jay Hoey, Executive Vice President Elekta North America.

MD Buyline measures user satisfaction based on evaluations by more than 3,300 hospitals in the member network. Founded in 1983, MD Buyline is a market intelligence organization that provides the healthcare industry with independent analysis and reporting.

 

###

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.